Abstract Aim of the work: Growth arrest-specific protein 6 (Gas6) and its soluble tyrosine kinase receptor sAxl are known to have antiapoptotic function which may be implicated in systemic lupus erythematosus (SLE) pathogenesis. We aimed to assess serum levels of GAS6 and its receptor sAxl in SLE patients and to correlate these levels with disease activity index and renal involvement.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease that may result from disturbed tolerance to self antigens and development of auto-antibodies leading to the formation of immune complexes [1] . These immune deposits in the tissues initiate an immune response by activating the complement cascade and recruiting inflammatory cells [2] . Although the exact etiology is not known, one of the possible triggers of this autoimmune reaction is the defective clearance of apoptotic cells [3, 4] .
Under normal circumstances, apoptotic cells are engulfed by macrophages and other phagocytic cells [5] . This provides a clearance of possible auto-antigens in the early phase of cell death without inducing inflammation or the immune response. In SLE, however, the clearance of apoptotic cells by macrophages is impaired, which may allow apoptotic cells to serve as immunogens for the induction of autoreactive T and B cells and drive the production of auto-antibodies [6] . The reasons for the defective clearance of apoptotic cells in SLE are not clear [5] .
Macrophages recognize apoptotic cells through an array of surface receptors that are present on the macrophages and dendritic cells. These tyrosine kinase receptors as tyro 3, axl, and mer of the TAM family may play an important role in the phagocytosis or clearance of apoptotic cells [7] .
Growth arrest-specific protein 6 (Gas6), a 75 kD multimodular vitamin K-dependent protein, is a similar protein to plasma anticoagulant protein S. Gas6 is expressed in many tissues, including capillary endothelial cells, vascular smooth muscle cells, and bone marrow cells. It was recognized as a growth factor-like molecule, as it interacted with tyrosine kinase receptors (TKR) of the TAM family [8] . TAM receptors undergo a proteolytic processing in the cell membrane, leading to increased plasma circulating levels of extracellular fragments of the receptors (soluble receptors). So, the membrane-bound Axl can be shed from the cell membrane as a result of proteolysis. These forms have been shown to interact with the ligands, modifying their function [9, 10] . Soluble forms of Axl (sAxl) which consist of the extracellular region of the protein and the ligand Gas6 are present in plasma at low concentrations. They increase in response to acute phase reactions [11] .
Apoptotic cells express phosphatidylserine (PS) on their surface, which bind directly to phagocytes via receptors such as several soluble proteins, including the TAM receptor ligands Gas6 and protein S [12] . In this process, a TAM ligand, Gas6, serves as a ''bridging molecule'' that physically links a TAM receptor, generally Mer or Axl, expressed on the surface of the phagocyte, to PS, on the surface of the apoptotic cell that will be engulfed [13] . Also, the Gas6/ TAM system regulates an intriguing mix of processes, including cell survival and proliferation, cell adhesion and migration, blood clot stabilization, and inflammatory cytokine release. There is evidence that Gas6 has a pivotal role in endothelial cell (EC) activation and participates in the interactions between ECs, platelets, and leukocytes during inflammation [14] .
Therefore, it is reasonable to hypothesize that one of the TAM receptor families (Axl) and one of its ligands, Gas6 might have an important role in the pathogenesis of SLE. So, the aim of the present study was to assess serum levels of Gas6 and its soluble tyrosine kinase receptor sAxl in SLE patients in comparison to healthy controls and to correlate those levels with SLE disease activity index and renal involvement.
Patients and methods
Fifty female SLE patients were selected from those presenting to the Rheumatology Department and Rheumatology and Rehabilitation outpatient Clinic of Ain Shams University Hospital. SLE patients were all fulfilling the updated American College of Rheumatology (ACR) revised criteria for the classification of SLE [15] . Patients with other inflammatory diseases, infections, malignancy or oral anticoagulant therapy were excluded.
The control group consisted of 40 healthy, age-matched females. The study protocol was in accordance with the Helsinki declaration of human rights, and was approved by the local Ethics Committee. The written informed consent from each patient and control was obtained.
All patients were subjected to the following: Statistical analysis: IBM SPSS statistical software package (V. 21.0, IBM Corp., USA, 2012) was used for data analysis. Data were expressed as range (minimum-maximum), mean and standard deviation (SD) for quantitative parametric data, and median and 25th and 75th percentiles for quantitative non parametric data. Nominal data were expressed as frequency and percentage. Comparison between two independent groups of numerical parametric data was done using Student's t-test and Mann-Whitney test for non parametric data. Pearson correlation coefficient test was done to study the correlation between two quantitative variables. Receiver operator characteristic (ROC) procedures identified optimal cut-off values for Gas6 to differentiate between SLE patients and controls, active and inactive SLE patients and patients with and without lupus nephritis. Probability of error at <0.05 was considered significant and highly significant at <0.001.
Results
This study included fifty female patients with SLE. Forty healthy female subjects served as the control group. The patients' age ranged from 18 to 56 years, with a mean of 32.24 ± 9.15 years, this was matched with the age of the control group that ranged from 20 to 54 years, with a mean age of 31.5 ± 8.91 years. The disease duration ranged from 0.5 to 13 years; with a mean of 4.1 + 3.5 years. The age of onset of the disease ranged from 17.5 to 44 years with a mean of 30.5 + 7.5 years.
SLE disease activity index ranged in SLE patients from 1 to 12 with a median of 6. SLE patients were subdivided according to the disease activity index into two groups: inactive SLE group including 18 patients (SLEDAI < 6) and active SLE group including 32 patients (SLEDAI P 6). SLE Patients were also subdivided according to presence or absence of lupus nephritis into another two subgroups: lupus nephritis group (n = 25) and kidney sparing SLE patient group (n = 25). Clinical and laboratory data of SLE patients are depicted in Tables 1 and 2 . Serum Gas6 and sAxl levels ranged from 26.5-49 ng/ml and 24.1-103.8 ng/ml respectively in SLE patients. When compared with a range of 3-9 ng/ml and 0.3-0.9 ng/ml in the control group, there was a highly significant elevation in serum Gas6 and sAxl levels in SLE patients versus controls (p < 0.001) ( Table 3 ). Serum Gas6 levels increased significantly in active SLE patients and lupus nephritis patients in comparison to inactive SLE patients and patients without renal involvement, respectively (p < 0.001). While, there were no significant differences regarding serum levels of sAxl when comparing these groups (Table 3 , Figs. 1 and 2) .
In SLE patients, serum Gas6 levels showed significant positive correlation with SLEDAI, ESR, anti-ds-DNA titre, proteinuria and negative correlation with serum C3 and C4 levels (p < 0.001), while, there were no significant correlations between serum Gas6 levels and both disease duration and age of onset of the disease (p > 0.05). There were no significant correlations between serum sAxl levels and all previous parameters (p > 0.05). Also, there were no significant correlations between serum sAxl levels and serum GAS6 levels (p > 0.05) ( Table 4) .
Receiver-operating characteristic (ROC) curve was applied to obtain the most sensitive and specific cut off level for Gas6 in order to discriminate active SLE patients (n = 32) from inactive patients (n = 18). Serum levels of Gas6 ranged from 33-95 ng/ml in active SLE patients and ranged from 15.5-28.5 ng/ml in inactive SLE patients. These two ranges are away from each other and both are self-discriminated. Values >28.5 ng/ml and <33 ng/ml can be considered best cutoff for discriminating active from those of inactive with 100% for all criteria (diagnostic specificity, diagnostic sensitivity, negative predictive value, positive predictive value and efficacy).
Discussion
Gas6 is a cell survival, proliferation and chemotactic factor and also a recognition bridge between phagocytes and apoptotic cells. Gas6 is present at a low concentration in plasma; however, it can be released by endothelial cells and leukocytes during inflammatory conditions [17] . Soluble Axl is the receptor that binds Gas6. It has an immune-regulatory role through modulating macrophage activation following an initial immune stimulus [18] . Our results showed that both serum Gas6 and sAxl were highly significantly increased in SLE patients compared to healthy controls. This was in agreement with Recarte-Pelz et al. [3] and Kim et al. [19] . The increased level of Gas6 may be explained by an increased production to promote the clearance of apoptotic bodies that are increased in SLE patients. In in vitro studies, Gas6 stimulates macrophage uptake of phosphatidyl serine liposomes which is blocked by the soluble extracellular domain of Axl (sAxl) [20] . Therefore, the high serum levels of Gas6 in SLE patients may be a result of a feedback loop induced by defective apoptotic bodies' uptake as a corrective mechanism of the immune system to enhance not only the apoptotic bodies' clearance but also to hold back the activation of excessive inflammatory response by the uncleared apoptotic bodies [19] . These results may give evidence to the possibility that the high serum levels of soluble form of Axl receptor may act as a blocker of macrophage and dendritic cells uptake of apoptotic bodies through the Gas6/ membrane bound Axl. This defect in clearance of apoptotic bodies results in the accumulation of apoptotic debris. It creates a viscous cycle producing further auto antibodies resulting in marked inflammation in SLE [21, 22] . In contrast to our results, Gheita et al. showed that the level of Gas6 was significantly reduced and its sAxl receptor increased compared to the control. This decrease in Gas6 was explained by its consumption in the apoptotic processes in SLE while the Figure 1 Comparison of serum concentrations of Gas6 and sAxl between inactive and active SLE subgroups. Figure 2 Comparison of serum concentrations of Gas6 and sAxl between lupus nephritis and kidney sparing SLE subgroups. Table 4 Correlations of serum Gas6 and sAxl levels in SLE patients with laboratory data and SLEDAI.
Parameter r (p value) Gas6 (ng/ml) sAxl(ng/ ESR: erythrocyte sedimentation rate; Pr/C: protein/creatinine ratio; C3: complement 3; C4: complement 4; SLEDAI: systemic lupus erythematosus disease activity index; Gas6: growth arrest-specific protein 6.
increase of Axl was explained by the continuous stimulation of the macrophage pool by apoptotic debris that may increase its expression and shedding [23] . On the other hand, other studies revealed that the plasma concentrations of Gas6 were almost identical between SLE patients and matched controls [17, 21] . This was explained by that almost all Gas6 present in healthy subjects is bound by soluble Axl. This may explain why there is actually little free Gas6 present in either normal controls or SLE patients serum [24] although the extent to which their ELISA can detect Axl-bound Gas6 has not been tested [21] .
In the present study, serum Gas6 levels showed highly significant increase among active SLE patients compared to inactive SLE patients. This was supported by the significant positive linear correlation between serum Gas6 levels and SLE-DAI in many studies [3, 19, 21, 25] . SLE is characterized by inflammatory vascular damage whereby the endothelial cells are affected. Although Gas6 is present in a low concentration in plasma, it can be released by endothelial cells and leukocytes during inflammatory conditions. Gas6 promotes EC activation and participates in the interactions between ECs, platelets, and leukocytes during inflammation [14] . Moreover, Gas6 has been shown to decrease the levels of secreted proinflammatory cytokines by DCs. The increased levels of Gas6 in active SLE patients compared to inactive patients are mostly referred to the increase in its down regulatory role in inflammation which becomes more prominent during periods of disease activity [3] . So, Gas6 signaling may have several effects, related to both the initiation of inflammation and the regulation of established inflammation [21] . In contrast to the present study, other studies did not find a significant difference in Gas6 levels among active and inactive groups [26, 27] though they found a trend of increased levels of Gas6 among certain presentations assessed in the SLEDAI score like in the patients with a history of neurological disorder and hematological flares [17] .
Our results also showed no significant difference in the serum sAxl levels between active and inactive SLE patients. Also, there was no significant correlation between sAxl and SLEDAI. This was in agreement with Recarte-Pelz et al. [3] . On the other hand, Ekman et al. [21] reported a significant correlation between sAxl and SLEDAI score. It is possible that sAxl is correlated only indirectly with the disease activity, and thus this correlation is lost in some populations [3] .
Most likely, the differences among studies are due to the intrinsic heterogeneity of the populations in each case. Another possible source of heterogeneity is the effect of specific genetic factors on plasma concentrations of Gas6 and sAxl. Different populations are likely to present differences in the genetic distribution of the alleles responsible for sAxl and Gas6 expression. This could be reflected in the plasma concentrations of the proteins under study. Indeed certain Gas6 variants showed considerable differences between populations from Europe and Asia [28, 29] .
Some studies have indicated that specific traits of SLE evaluated in SLEDAI, such as nephritis [21, 25] or neurologic disorder [17] , affect the values of Gas6 or sAxl receptors. The focus of the present study was to elucidate the relation between both serum Gas6 and sAxl and lupus renal affection. A highly significant increase of serum Gas6 among the lupus nephritis group was demonstrated. However, sAxl failed to show any significant difference between the two groups. Ekman et al. showed that serums Gas6 as well as sAxl were significantly higher in patients with lupus nephritis than in patients without nephritis [21] . Interestingly, Gas6 and Axl have been implicated to be important in experimental glomerulonephritis (GN) in mice, as well as diabetic and nephrotoxic nephritis. Gas6 À/À mice were protected in experimental glomerulonephritis and nephrotoxic nephritis, and those results suggested that Gas6 could be important in inflammation of experimental glomerulonephritis and nephrotoxic nephritis [30, 31] . Gas6 may have a special role in renal pathophysiology especially in SLE. Gas6 roles in vascular biology through activation of receptor tyrosine kinases resulting in vascular smooth muscle cell proliferation, adhesion and migration and inhibition of leukocytes adhesion to endothelial cells in the presence of chemoattractants may add reasonable proof for this postulation [27] .
In conclusion, increased serum Gas6 and sAxl levels in SLE patients may be due to defect in the clearance of apoptotic bodies; one of the possible triggers of autoimmune reaction in SLE patients. Serum Gas6 can be used as an activity marker and gives also an idea about the severity of renal involvement. On the other hand, serum sAxl levels had no significant association with disease activity or renal involvement. So, screening of activity of SLE and severity of renal involvement is recommended by measuring serum Gas6 for better assessment and management of the disease.
